Sense Biodetection’s range of molecular diagnostics tests target infectious disease applications such as influenza (flu). Credit: Cynthia Goldsmith.

UK-based molecular diagnostics firm Sense Biodetection has raised £12.3m for the development and manufacture of a range of instrument-free, point-of-care molecular diagnostic products.

The company has raised £10.5m through a Series A funding round, which was co-led by Cambridge Innovation Capital (CIC) and Earlybird.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Jonathan Milner and seed round investor Mercia Asset Management also took part in the funding round.

Along with the investment, Sense secured a grant of £1.8m from Innovate UK.

Sense Biodetection CEO Harry Lamble said: “We are delighted to secure the funding necessary to conduct the formal development of our first products. With the support of an exceptional new investment syndicate, Sense is positioned to become first-in-class and best-in-class in the exciting field of instrument-free molecular diagnostics and to realise our vision to transform healthcare through decentralisation.”

CIC’s Mike Anstey said: “We’re delighted to co-lead Sense’s Series A financing, enabling this ambitious company to develop its pipeline of transformational products. CIC’s investment strategy is to build high-growth companies with differentiated, innovative technology within the Cambridge ecosystem, and Sense is a great example of this.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company uses rapid molecular amplification technology in its range of molecular diagnostics tests to target infectious disease applications such as influenza (flu).

According to the company, the field of molecular diagnostics is dominated by machine-based tests, but the systems and procedures needed to operate and maintain machines pose challenges at the point of care.

Sense Biodetection claim that its instrument-free molecular diagnostics could serve as a flexible test format given that it can be used by a wide range of potential users and in any setting.

The products can carry out rapid tests for viral and bacterial pathogens, such as those causing respiratory infections, within a short period.